We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

21 hedge funds and large institutions have $2.44M invested in Benitec Biopharma in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $2.09M → $2.44M (+$352K)

0.14% less ownership

Funds ownership: 2.59% → 2.45% (-0.14%)

16% less funds holding

Funds holding: 25 → 21 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
21
Holders Change
-4
Holders Change %
-16%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$9.75K
2
PAG
Private Advisor Group
New Jersey
+$3.15K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$77.5K
2
Renaissance Technologies
Renaissance Technologies
New York
-$36.1K
3
Walleye Capital
Walleye Capital
New York
-$30.7K
4
TSS
Two Sigma Securities
New York
-$9.36K
5
Jane Street
Jane Street
New York
-$4.67K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$2.1M – – –
SCM
2
Suvretta Capital Management
New York
$161K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$47K -$36.1K -8,862 -40%
Walleye Capital
4
Walleye Capital
New York
$45.3K -$30.7K -7,531 -37%
VF
5
Virtu Financial
New York
$26K +$9.75K +2,391 +50%
Vanguard Group
6
Vanguard Group
Pennsylvania
$15.7K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$10.1K -$298 -73 -3%
Morgan Stanley
8
Morgan Stanley
New York
$9.55K -$77.5K -19,025 -88%
Two Sigma Investments
9
Two Sigma Investments
New York
$5.61K -$530 -130 -8%
CF
10
Cantor Fitzgerald
New York
$5.26K – – –
State Street
11
State Street
Massachusetts
$4.5K – – –
PAG
12
Private Advisor Group
New Jersey
$2.76K +$3.15K +774 New
WA
13
WealthTrust Axiom
Pennsylvania
$2.72K – – –
CAN
14
Cetera Advisor Networks
California
$2.59K -$1.02K -251 -26%
Northern Trust
15
Northern Trust
Illinois
$2.48K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$2K – – –
Group One Trading
17
Group One Trading
Illinois
$315 – – –
MHR
18
Matthew Hamilton Rosenberg
$80 – – –
UBS Group
19
UBS Group
Switzerland
$73 -$224 -55 -73%
Wells Fargo
20
Wells Fargo
California
$41 – – –
TSS
21
Two Sigma Securities
New York
– -$9.36K -3,240 Closed
Jane Street
22
Jane Street
New York
– -$4.67K -1,616 Closed
Two Sigma Advisers
23
Two Sigma Advisers
New York
– -$3.94K -1,365 Closed
HF
24
HRT Financial
New York
– -$1K -675 Closed

BNTC Hedge Fund Activity: Q1 2023 in Review

21 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2023, worth a combined $2.44M — up 17% from $2.09M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BNTC and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, adding an estimated $9.75K. The largest seller was Morgan Stanley, cutting an estimated $77.5K.

  • 21 institutional investors held Benitec Biopharma (BNTC) as of Q1 2023, down from 25 in Q4 2022.
  • Funds reported $2.44M of Benitec Biopharma stock for Q1 2023, up 17% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest Benitec Biopharma buyer in Q1 2023 was Virtu Financial, an estimated $9.75K added.
  • The largest Benitec Biopharma seller in Q1 2023 was Morgan Stanley, an estimated $77.5K sold.

Based on aggregated 13F filings for Q1 2023.